Mike Garrison's Retirement Marks the End of an Era at BD

Mike Garrison's Retirement: A Legacy at BD

In a significant announcement from BD (Becton, Dickinson and Company), it was revealed that Dr. Michael (Mike) Garrison will be retiring on October 2, 2026, after two decades of impactful service to the global medical technology giant. As the current executive vice president and president of the Medical Essentials and BioPharma Systems segments, Garrison's departure marks a pivotal point in the company's leadership journey.

Garrison’s career at BD began in 2005, and throughout his tenure, he has held various leadership roles that have been critical in shaping the company’s strategic direction. Prior to his current position, he served as executive vice president and president of BD’s Medical segment, and was also the worldwide president of both Medication Management Solutions and Surgery. His deep expertise in research and development, along with his marketing experience in the MedTech industry, have been invaluable assets to BD’s continuous growth and innovation.

Reflecting on Garrison's contributions, Tom Polen, Chairman, CEO, and President of BD, expressed gratitude for Garrison’s leadership: "Mike has made a significant impact on BD over the past two decades, helping guide our company through periods of transformation while always keeping our customers, patients, and associates at the center of his decisions." Polen emphasized Garrison's role in building strong teams and developing exceptional leaders, which have positioned BD for future success.

As Garrison prepares for his retirement, he will remain in his current role until the end of the fiscal year, ensuring a seamless transition for the company. A thorough search is underway to find his successor as the president of the Medical Essentials segment. Meanwhile, BioPharma Systems will report directly to Polen, reflecting its importance as a vital growth driver for BD.

"It has been a privilege to spend more than two decades at BD, working alongside talented teams who are deeply committed to improving healthcare around the world," Garrison stated in his farewell address. He expressed appreciation for the people and the mission that have made his years at BD meaningful. Looking forward, he is optimistic about the company’s future in advancing care and technology.

BD, known as one of the largest pure-play medical technology companies globally, has a mission to enhance health worldwide by innovating across various sectors, including medical essentials, connected care, biopharma systems, and interventional technologies. With a workforce of over 60,000, BD supports healthcare professionals by providing transformative technologies that optimize clinical operations and enhance patient care. The company’s commitment to improving health outcomes while reducing costs has made a significant impact on global healthcare practices.

In conclusion, Dr. Mike Garrison’s retirement signifies the end of an era for BD but his legacy will undoubtedly influence the company for years to come. As he embarks on this new chapter, the healthcare industry reflects on his vast contributions, and BD prepares to continue its journey of innovation and care.